<DOC>
	<DOCNO>NCT01613586</DOCNO>
	<brief_summary>In study several dose level ASP3652 , give orally 12 week , compare placebo treatment female patient Bladder Pain Syndrome / Interstitial Cystitis .</brief_summary>
	<brief_title>A Randomized Study Comparing Placebo ASP3652 Treatment Women With Bladder Pain Syndrome / Interstitial Cystitis ( BPS/IC )</brief_title>
	<detailed_description>This study consist screen phase , initial 3 week Run-in period , 12 week Treatment period 2 week Follow-up ( FU ) period . This study investigate efficacy safety 12 week treatment ASP3652 female patient Bladder Pain Syndrome / Interstitial Cystitis ( BPS/IC ) . Different dose level ASP3652 compare placebo . ASP3652 administer oral tablet . The objective study investigate efficacy ASP3652 patient BPS/IC , ass optimal dose ASP3652 , investigate safety tolerability investigate pharmacokinetics pharmacodynamics ASP3652 patient BPS/IC out-patient setting .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<criteria>Has previously diagnose BPS/IC ; i.e. , pelvic pain , pressure discomfort perceive related urinary bladder accompany least one urinary symptom persistent urge void frequency , least 3 month prior screen absence urinary infection obvious pathology identifiable cause Has enrolment score 4 great 11point ( 010 ) NRS average pain previous week , item 4 FGUPI Has mean pain score 4.0 great 11point ( 010 ) NRS daily assess pain ( item 4 FGUPI24H ) last 7 day prior randomization Is willing comply study requirement complete questionnaire diary attend study visit practice birth control Undergone cystoscopy hydrodistension undergone Botox injection bladder within 6 month prior screen Use pentosan polysulphate sodium within 4 week prior screen Any intravesicular pharmacological treatment intervention BPS/IC bladder , urethral , ureteral , pelvic peripelvic invasive procedure within 3 month prior screen Cystitis document symptomatic bacterial cystitis last 3 month prior screen Lower urinary tract malignancy , positive ( micro ) hematuria urine sediment Neurologic disease defect affect bladder function symptomatic urethral diverticulum postpartum surgery related genital tract condition , symptomatic bladder ureteral calculus Post Void Residual volume great 150 mL Clinically significant abnormality observe cystoscopy transabdominal ultrasound Currently active treat sexual transmittable disease Substance abuse use delta9tertrahydrocannabinol ( THC ) assess positive urine test THC screen Any clinically relevant concomitant disease ( past present ) would , opinion investigator , put subject risk mask measure efficacy Symptoms depression , define Center Epidemiological Studies Depression Scale score 27 Use steroid , immunomodulators , cytochrome P4502C8 inhibitor , cannabis / THC base medication , opioid analgesic antiviral / antibacterial / antifungal agent last 4 week screen Initiation , discontinuation , variation dose antidepressant , anticonvulsant , antimuscarinics , benzodiazepine , skeletal muscle relaxant , nonsteroid antiinflammatory drug , non opioid analgesic , homeopathic medication herbal therapy last 4 week screen . Subjects continue medication stable dose throughout study Clinically relevant abnormal urine blood safety laboratory value active hepatic and/or biliary disease ( AST ALT &gt; 2 time upper limit normal , total bilirubin &gt; 1.5 time upper limit normal ) Participated clinical study treat investigational drug device within 84 day period stipulate local regulation , whichever longer , prior screen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Interstitial Cystitis</keyword>
	<keyword>Bladder Pain Syndrome</keyword>
	<keyword>Painful Bladder Syndrome</keyword>
	<keyword>ASP3652</keyword>
</DOC>